You are here

Coronary Intervention & Surgery


Hospitals ranked in the top 50 for cardiology and heart surgery by U.S. News and World Report appear no better at performing PCI than unranked hospitals, according to an analysis of more than 500,000 procedures performed at 654 hospitals.

PCI of chronic total occlusions (CTOs) can be safely performed by expert operators and provides significant benefit to patients with reduced left ventricular ejection fraction (LVEF) or diabetes, according to a series of studies published Nov. 13 in JACC: Cardiovascular Interventions.

Scaffold discontinuity, malapposition and neoatherosclerosis were found to be the leading mechanisms behind very late scaffold thrombosis (VLScT) in cardiac patients implanted with bioresorbable devices, investigators from the INVEST registry have reported.

Recent studies have shown robotic PCI to be a feasible way to treat coronary artery disease. But at the annual Transcatheter Cardiovascular Therapeutics (TCT) conference Oct. 30, Ryan D. Madder, MD, took the conversation a step further: Will it eventually be possible to perform “tele-stenting” over long distances?

Research presented Nov. 2 at the Transcatheter Cardiovascular Therapeutics scientific symposium in Denver demonstrates patients with stable coronary artery disease (CAD) and abnormal fractional flow reserve (FFR) derive better clinical outcomes with PCI at similar cost to medical therapy alone.


Recent Headlines

Communication, coordination among hospital leaders and physicians improve surgical outcomes

In October 2010, some hospitals in South Carolina began implementing a customized surgical safety checklist patterned after a checklist that the World Health Organization developed. Hospitals implemented the 12-step process that focused on teamwork, training and monitoring progress.

SCAI announces late-breaking clinical trials sessions

The Society for Cardiovascular Angiography and Interventions (SCAI) recently announced the late-breaking clinical trials sessions for the SCAI 2017 scientific sessions.

FDA approves Medtronic’s Resolute Onyx drug-eluting stent

The U.S. Food and Drug Administration (FDA) approved the Resolute Onyx drug-eluting stent for adults with coronary artery disease.

Risk score may help predict mortality in cardiogenic shock patients

Researchers in Germany have developed a risk prediction score that strongly correlated with mortality in patients who suffer from cardiogenic shock following an acute MI.

Cardiologist treats first patient in study evaluating orbital atherectomy system

Cardiovascular Systems recently announced the first patient had enrolled in the company’s ECLIPSE trial, which is evaluating its Diamondback 360 coronary orbital atherectomy system.

AATS releases guidelines on concomitant surgical ablation in AFib patients

Patients with atrial fibrillation (AFib) who undergo concomitant surgical ablation have an improvement in 30-day operative mortality, long-term survival and health-related quality of life, according to new expert consensus guidelines from the American Association for Thoracic Surgery (AATS).

Hospitals using surgical safety checklists have 22 percent lower 30-day mortality rates

Hospitals in South Carolina that completed a voluntary, team-based surgical safety checklist had a significantly lower rate of 30-day post-operative mortality compared with hospitals that did not complete the program by the end of 2013, according to a population-based study.

Most patients with cardiovascular disease do not see a provider before having a STEMI

Fewer than half of patients with cardiovascular disease saw a primary care provider and fewer than 40 percent saw a cardiovascular provider during the two years before they had a ST-segment elevation MI (STEMI), according to a prospective cohort study.

PinnacleHealth to test efficacy of stroke reduction TAVR tool

In a new clinical trial at PinnacleHealth, based in Harrisburg, Pennsylvania, researchers are testing the efficacy of the Keystone Heart TriGuard, a device designed to reduce the risk of stroke during transcatheter aortic valve replacement (TAVR) procedures.

Abbott restricts use of Absorb BVS in Europe

Abbott Vascular has restricted the use of its Absorb and Absorb GT1 bioresorbable vascular scaffolds (BVS) in Europe to clinical registries.